POINT Biopharma to Host Virtual Education Event on December 6, 2021

Rhea-AI Summary

POINT Biopharma Global Inc. (NASDAQ: PNT) will host a virtual educational event titled “The First Principles of Radiopharmaceuticals” on December 6, 2021, at 12:00 PM ET. The event is designed to provide insights into the unique qualities of radiopharmaceuticals in cancer treatment, including their manufacturing processes and short shelf lives. Attendees, including investors and industry stakeholders, will gain a deeper understanding of radiopharmaceuticals, highlighted by discussions led by the company's executive team. Registration is open online.

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations

Register online at https://hub.pointbiopharma.com/dec2021

INDIANAPOLIS, Nov. 22, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced that it will host a virtual education event titled “The First Principles of Radiopharmaceuticals” on Monday, December 6, 2021 at 12:00 pm ET. Registration for the event is now open at https://hub.pointbiopharma.com/dec2021. The event will feature a presentation and an interactive Q&A session from the Company’s executive leadership team including, Dr. Joe McCann, Chief Executive Officer and Dr. Neil Fleshner, Chief Medical Officer.

Radiopharmaceuticals offer unique qualities that make them a precise and powerful tool for the treatment of cancer. But they are unique from most other pharmaceuticals: they are manufactured just-in-time and have very short shelf lives. This event will cover the “First Principles of Radiopharmaceuticals” to educate investors, analysts, partners, and industry stakeholders on the journey From Neutron To Patient^TM. Audience members will leave with a broader understanding of how radiopharmaceuticals work, their strengths and weaknesses, considerations that impact their design, as well as how they are made.

About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is transforming precision medicine by combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like Actinium-225 and Lutetium-177.
https://www.pointbiopharma.com/

Contact:
Ari Shomair
media@pointbiopharma.com
(647) 812-2417

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
investors@pointbiopharma.com

FAQ

What is the date of POINT Biopharma's educational event on radiopharmaceuticals?

POINT Biopharma's educational event titled 'The First Principles of Radiopharmaceuticals' will be held on December 6, 2021.

How can I register for the POINT Biopharma event on December 6, 2021?

You can register for the POINT Biopharma event online at their official website.

What topics will be covered in the POINT Biopharma radiopharmaceuticals event?

The event will cover the unique qualities of radiopharmaceuticals, including their manufacturing processes, strengths, weaknesses, and therapeutic benefits.

Who will present at the POINT Biopharma educational event?

The event will feature presentations from Dr. Joe McCann, CEO, and Dr. Neil Fleshner, CMO of POINT Biopharma.

What is the significance of radiopharmaceuticals in cancer treatment as discussed by POINT Biopharma?

Radiopharmaceuticals are significant in cancer treatment due to their precise targeting and effectiveness, despite having short shelf lives.